ClinicalTrials.gg
RecruitingNCT06300853COVaxFragileUpdated Mar 8, 2024

Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.

An interventional study of Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses in COVID-19, sponsored by IRCCS Sacro Cuore Don Calabria di Negrar. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by IRCCS Sacro Cuore Don Calabria di Negrar · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2023, registered Mar 2024).
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
350
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 392 studies in COVID-19 with a site in Italy — 37 open to participants now, 46 under way, 7 of them phase 3. COVID-19 · Italy.

Planned enrollment
36th of 153
350 · median 100
Started
2023
with 9 others
No phase
60 of 392
5 open now
Primary completion
2025-11
later than 26 of 45 live
Registered
366th of 392
by date

Among the 392 studies in COVID-19 with a site in Italy, this one is the 36th largest by planned enrollment of the 153 interventional ones that give a count, is one of 10 that started in 2023, is one of 60 with no phase, reaches primary completion later than 26 of the 45 other live ones, and was the 366th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

37 of the 392 studies in COVID-19 with a site in Italy are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 392 studies in COVID-19 with a site in Italy, or all of them as a file.
02

Study summary

This is an experimental study without drug and device, non-profit, single-center.

The general objective of the project is to study how the adaptive immune response evolves against SARS-CoV-2 with repeated vaccination boosters and infections also in relation to the evolution of variations. This study will be relevant to frail populations who are the main targets of repeated vaccinations. Our project will benefit from the availability of a highly cohort characterized of vaccinated people, including cancer patients and elderly people, with prospective collection of samples for an in-depth evaluation of the evolution of the immune response with repeated exposure to doses of infection or vaccine. As part of the study, analyzes will be carried out on samples of patients enrolled in a manner prospective at the oncology departments of the IRCCS (Medical Oncology, Department of Radiotherapy advanced oncology and nuclear medicine) and elderly patients residing in retirement homes of the IRCCS. Patients will also be asked for consent to store any residual samples in the Tropica DITM Biobank.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Cancer patients

Inclusion criteria:

  • Age> 18 years.
  • Solid tumor diagnosis [I, II, III, IV stage,].
  • Vaccinated with anti-SARS-CoV-2 vaccine or/and having history of past SARS-CoV-2 infections.
  • Signed .

Exclusion criteria

  • Age \< 18 years.
  • Absence of signed informed consent.

Elderly subjects

Inclusion criteria:

  • Age> 70 years.
  • Vaccinated with anti-SARS-CoV-2 vaccine or/and having history of past SARS-CoV-2 infections.
  • Signed informed consent.

Exclusion criteria

  • Age \< 70 years.
  • Absence of signed informed consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Other
    Cancer patients

    Adult patients with a solid tumor diagnosis \[I, II, III, IV stage,\] and active anti-cancer treatment or treatment discontinued for less than 6 months, followed at IRCCS Sacro Cuore - Don Calabria, Negrar (Verona), Italy will be prospectively recruited at the moment of the future booster doses administration of SARS-CoV-2 vaccine.

    Other: Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses

  • Other
    Elderly subjects

    Subjects over 70 years of age who live in the nursing home in the social area at the IRCCS Sacro Cuore - Don Calabria Hospital will be prospectively recruited at the moment of the future booster doses administration of SARS-CoV-2 vaccine.

    Other: Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses

Interventions

  • OtherAnalisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses

    Whole blood and serum samples will be longitudinally collected at the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1). Possible further time points will be collected within 2 years, based on the National recommended future vaccination regimens. Biological samples will be used for the following exams: * Cellular immunity characterization * T- and B-cells Immunophenotype. * Specific T-cell response. * In vitro specific B-cells characterization. * Antibody-dependent cellular cytotoxicity. * Humoral response characterization * Serology assays. * Avidity assay. * Neutralization assays with different SARS-CoV-2 variants. * Presence of specific or cross-reactive antibodies for common hCoV. * Genetic and epigenetic analysis

06

What researchers measure

Primary outcomes

  1. Cellular response evaluation: flow cytometry profiles (proportions of cells)

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  2. Cellular response evaluation: results of T and B cells stimulation with specific peptides (continuous variables, unity of measure: Optical Density OD)

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  3. Cellular response evaluation: ADCC assay (continuous variables, unity of measure: Optical Density OD)

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  4. Cellular response evaluation: anti-SARS-CoV-2 antibodies quantities (IgGs and IgM, BAU/ml)

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  5. Cellular response evaluation: neutralization assays against different SARS-CoV-2 variants (continuous variables, unity of measure: TCID50/ml)

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  6. Cellular response evaluation: avidity assays (continuous variables, unity of measure: BAU/ml).

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  7. Humoral response evaluation: anti-SARS-CoV-2 antibodies quantities (IgGs and IgM, BAU/ml)

    a) A b) Analysis results of , c) Analysis results of

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  8. Humoral response evaluation: neutralization assays against different SARS-CoV-2 variants (continuous variables, unity of measure: TCID50/ml)

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  9. Humoral response evaluation: avidity assays (continuous variables, unity of measure: BAU/ml).

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

Secondary outcomes

  1. Neutralization assays against different human Coronavirus (hCoV).

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

  2. Whole genome sequencing analysis results

    Time frame: At the moment of the administration of the booster doses (T0) and three weeks after the booster doses (T1).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2025, 24 months after the start.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 24 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Mar 8, 2024
StartActual
Nov 14, 2023
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06300853
Lead sponsor
IRCCS Sacro Cuore Don Calabria di Negrar
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Nov 14, 2023
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Mar 8, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion